Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Overweight and obese children with optimal control in the T1D Exchange Registry: How are they different from lean children with optimal control?

Flokas ME, Zeymo A, Mete M, Anhalt H, Rother KI, Gourgari E.

J Diabetes Complications. 2020 Apr;34(4):107513. doi: 10.1016/j.jdiacomp.2019.107513. Epub 2019 Dec 30.

PMID:
32007420
3.

SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.

Taylor SI, Blau JE, Rother KI, Beitelshees AL.

Lancet Diabetes Endocrinol. 2019 Dec;7(12):949-958. doi: 10.1016/S2213-8587(19)30154-8. Epub 2019 Oct 1. Review.

PMID:
31585721
4.

Maternal Exposure to Non-nutritive Sweeteners Impacts Progeny's Metabolism and Microbiome.

Olivier-Van Stichelen S, Rother KI, Hanover JA.

Front Microbiol. 2019 Jun 20;10:1360. doi: 10.3389/fmicb.2019.01360. eCollection 2019.

5.

Low-calorie sweetener use, weight, and metabolic health among children: A mini-review.

Young J, Conway EM, Rother KI, Sylvetsky AC.

Pediatr Obes. 2019 Aug;14(8):e12521. doi: 10.1111/ijpo.12521. Epub 2019 Apr 14. Review.

PMID:
30983091
6.

Trends in Low-Calorie Sweetener Consumption Among Pregnant Women in the United States.

Sylvetsky AC, Figueroa J, Rother KI, Goran MI, Welsh JA.

Curr Dev Nutr. 2019 Jan 15;3(4):nzz004. doi: 10.1093/cdn/nzz004. eCollection 2019 Apr.

7.

Low cholesterol efflux capacity and abnormal lipoprotein particles in youth with type 1 diabetes: a case control study.

Gourgari E, Playford MP, Campia U, Dey AK, Cogen F, Gubb-Weiser S, Mete M, Desale S, Sampson M, Taylor A, Rother KI, Remaley AT, Mehta NN.

Cardiovasc Diabetol. 2018 Dec 19;17(1):158. doi: 10.1186/s12933-018-0802-0.

8.

Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.

Parker VER, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, Sapp JC, Andrews K, Bardou M, Chen KY, Darling TN, Gautier E, Goldspiel BR, Hadj-Rabia S, Harris J, Kounidas G, Kumar P, Lindhurst MJ, Loffroy R, Martin L, Phan A, Rother KI, Widemann BC, Wolters PL, Coubes C, Pinson L, Willems M, Vincent-Delorme C; PROMISE Working Group, Vabres P, Semple RK, Biesecker LG.

Genet Med. 2019 May;21(5):1189-1198. doi: 10.1038/s41436-018-0297-9. Epub 2018 Oct 1.

9.

How Non-nutritive Sweeteners Influence Hormones and Health.

Rother KI, Conway EM, Sylvetsky AC.

Trends Endocrinol Metab. 2018 Jul;29(7):455-467. doi: 10.1016/j.tem.2018.04.010. Epub 2018 May 30. Review.

PMID:
29859661
10.

Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.

Blau JE, Bauman V, Conway EM, Piaggi P, Walter MF, Wright EC, Bernstein S, Courville AB, Collins MT, Rother KI, Taylor SI.

JCI Insight. 2018 Apr 19;3(8). pii: 99123. doi: 10.1172/jci.insight.99123. eCollection 2018 Apr 19.

11.

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R.

J Clin Invest. 2018 Jul 2;128(7):3041-3052. doi: 10.1172/JCI98814. Epub 2018 Jun 11.

12.

Nonnutritive Sweeteners in Weight Management and Chronic Disease: A Review.

Sylvetsky AC, Rother KI.

Obesity (Silver Spring). 2018 Apr;26(4):635-640. doi: 10.1002/oby.22139. Review.

13.

Factitious hypoglycemia in children and adolescents with diabetes.

Bauman V, Sturkey AC, Sherafat-Kazemzadeh R, McEwan J, Jones PM, Keating A, Isganaitis E, Ricker A, Rother KI.

Pediatr Diabetes. 2018 Jun;19(4):823-831. doi: 10.1111/pedi.12650. Epub 2018 Feb 21. Review.

14.

Response to 'Letter to the Editor: regarding Sylvetsky et al. 2017 Plasma concentrations of sucralose in children and adults'.

Meni Sylvetsky AC, Rother KI.

Toxicol Environ Chem. 2017;99(4):732-733. doi: 10.1080/02772248.2017.1288317. Epub 2017 Mar 1. No abstract available.

15.

Low-Calorie Sweeteners: Disturbing the Energy Balance Equation in Adolescents?

Sylvetsky AC, Jin Y, Mathieu K, DiPietro L, Rother KI, Talegawkar SA.

Obesity (Silver Spring). 2017 Dec;25(12):2049-2054. doi: 10.1002/oby.22005. Epub 2017 Oct 31.

16.

Pharmacokinetics of Sucralose and Acesulfame-Potassium in Breast Milk Following Ingestion of Diet Soda.

Rother KI, Sylvetsky AC, Walter PJ, Garraffo HM, Fields DA.

J Pediatr Gastroenterol Nutr. 2018 Mar;66(3):466-470. doi: 10.1097/MPG.0000000000001817.

17.

A High-Carbohydrate, High-Fiber, Low-Fat Diet Results in Weight Loss among Adults at High Risk of Type 2 Diabetes.

Sylvetsky AC, Edelstein SL, Walford G, Boyko EJ, Horton ES, Ibebuogu UN, Knowler WC, Montez MG, Temprosa M, Hoskin M, Rother KI, Delahanty LM; Diabetes Prevention Program Research Group.

J Nutr. 2017 Nov;147(11):2060-2066. doi: 10.3945/jn.117.252395. Epub 2017 Sep 27.

18.

Development of Sweet Taste Perception: Implications for Artificial Sweetener Use.

Sylvetsky AC, Conway EM, Malhotra S, Rother KI.

Endocr Dev. 2017;32:87-99. doi: 10.1159/000475733. Epub 2017 Aug 15. Review.

PMID:
28873386
19.

Plasma concentrations of sucralose in children and adults.

Sylvetsky AC, Bauman V, Blau JE, Garraffo HM, Walter PJ, Rother KI.

Toxicol Environ Chem. 2017;99(3):535-542. doi: 10.1080/02772248.2016.1234754. Epub 2016 Oct 17.

20.

Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.

Blau JE, Tella SH, Taylor SI, Rother KI.

Diabetes Metab Res Rev. 2017 Nov;33(8). doi: 10.1002/dmrr.2924. Epub 2017 Sep 29.

21.

Exenatide Improves HDL Particle Counts and Size Distribution in Patients With Long-standing Type 1 Diabetes.

Gourgari EA, Mete M, Sampson ML, Harlan DM, Remaley AT, Rother KI.

Diabetes Care. 2017 Jul;40(7):e88-e89. doi: 10.2337/dc16-2602. Epub 2017 May 17. No abstract available.

22.

Pigment Epithelium-Derived Factor Declines in Response to an Oral Glucose Load and Is Correlated with Vitamin D and BMI but Not Diabetes Status in Children and Young Adults.

Sylvetsky AC, Issa NT, Chandran A, Brown RJ, Alamri HJ, Aitcheson G, Walter M, Rother KI.

Horm Res Paediatr. 2017;87(5):301-306. doi: 10.1159/000466692. Epub 2017 Apr 11.

23.

Effects of Metreleptin in Pediatric Patients With Lipodystrophy.

Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, Gorden P.

J Clin Endocrinol Metab. 2017 May 1;102(5):1511-1519. doi: 10.1210/jc.2016-3628.

24.

Widespread sucralose exposure in a randomized clinical trial in healthy young adults.

Sylvetsky AC, Walter PJ, Garraffo HM, Robien K, Rother KI.

Am J Clin Nutr. 2017 Apr;105(4):820-823. doi: 10.3945/ajcn.116.144402. Epub 2017 Feb 22.

25.

Consumption of Low-Calorie Sweeteners among Children and Adults in the United States.

Sylvetsky AC, Jin Y, Clark EJ, Welsh JA, Rother KI, Talegawkar SA.

J Acad Nutr Diet. 2017 Mar;117(3):441-448.e2. doi: 10.1016/j.jand.2016.11.004. Epub 2017 Jan 10.

26.

Hormonal responses to non-nutritive sweeteners in water and diet soda.

Sylvetsky AC, Brown RJ, Blau JE, Walter M, Rother KI.

Nutr Metab (Lond). 2016 Oct 21;13:71. eCollection 2016.

27.

The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T.

J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511. Epub 2016 Oct 6. Review.

28.

Trends in the consumption of low-calorie sweeteners.

Sylvetsky AC, Rother KI.

Physiol Behav. 2016 Oct 1;164(Pt B):446-450. doi: 10.1016/j.physbeh.2016.03.030. Epub 2016 Mar 31. Review.

29.

Understanding the metabolic and health effects of low-calorie sweeteners: methodological considerations and implications for future research.

Sylvetsky AC, Blau JE, Rother KI.

Rev Endocr Metab Disord. 2016 Jun;17(2):187-94. doi: 10.1007/s11154-016-9344-5. Review.

30.

Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.

Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q, Montealegre G, Biancotto A, Reinhardt A, de Jesus AA, Pelletier M, Tsai WL, Remmers EF, Kardava L, Hill S, Kim H, Lachmann HJ, Megarbane A, Chae JJ, Brady J, Castillo RD, Brown D, Casano AV, Gao L, Chapelle D, Huang Y, Stone D, Chen Y, Sotzny F, Lee CC, Kastner DL, Torrelo A, Zlotogorski A, Moir S, Gadina M, McCoy P, Wesley R, Rother KI, Hildebrand PW, Brogan P, Krüger E, Aksentijevich I, Goldbach-Mansky R.

J Clin Invest. 2016 Feb;126(2):795. doi: 10.1172/JCI86020. Epub 2016 Feb 1. No abstract available.

31.

Buddy Study: Partners for better health in adolescents with type 2 diabetes.

Sylvetsky AC, Nandagopal R, Nguyen TT, Abegg MR, Nagarur M, Kaplowitz P, Rother KI.

World J Diabetes. 2015 Dec 25;6(18):1355-62. doi: 10.4239/wjd.v6.i18.1355.

32.

Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.

Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q, Montealegre G, Biancotto A, Reinhardt A, Almeida de Jesus A, Pelletier M, Tsai WL, Remmers EF, Kardava L, Hill S, Kim H, Lachmann HJ, Megarbane A, Chae JJ, Brady J, Castillo RD, Brown D, Casano AV, Gao L, Chapelle D, Huang Y, Stone D, Chen Y, Sotzny F, Lee CC, Kastner DL, Torrelo A, Zlotogorski A, Moir S, Gadina M, McCoy P, Wesley R, Rother KI, Hildebrand PW, Brogan P, Krüger E, Aksentijevich I, Goldbach-Mansky R.

J Clin Invest. 2015 Nov 2;125(11):4196-211. doi: 10.1172/JCI81260. Epub 2015 Oct 20. Erratum in: J Clin Invest. 2016 Feb;126(2):795. Rother, Kristina [corrected to Rother, Kristina I].

33.

Non-nutritive sweeteners in breast milk: perspective on potential implications of recent findings.

Rother KI, Sylvetsky AC, Schiffman SS.

Arch Toxicol. 2015 Nov;89(11):2169-71. doi: 10.1007/s00204-015-1611-9. Epub 2015 Oct 14. No abstract available.

34.

Nonnutritive Sweeteners in Breast Milk.

Sylvetsky AC, Gardner AL, Bauman V, Blau JE, Garraffo HM, Walter PJ, Rother KI.

J Toxicol Environ Health A. 2015;78(16):1029-32. doi: 10.1080/15287394.2015.1053646. Epub 2015 Aug 12.

35.

Positive association between artificially sweetened beverage consumption and incidence of diabetes.

Sylvetsky Meni AC, Swithers SE, Rother KI.

Diabetologia. 2015 Oct;58(10):2455-6. doi: 10.1007/s00125-015-3694-5. Epub 2015 Jul 18. No abstract available.

36.

Long-term immunosuppression after solitary islet transplantation is associated with preserved C-peptide secretion for more than a decade.

Blau JE, Abegg MR, Flegel WA, Zhao X, Harlan DM, Rother KI.

Am J Transplant. 2015 Nov;15(11):2995-3001. doi: 10.1111/ajt.13383. Epub 2015 Jul 16.

37.

SGLT2 Inhibitors May Predispose to Ketoacidosis.

Taylor SI, Blau JE, Rother KI.

J Clin Endocrinol Metab. 2015 Aug;100(8):2849-52. doi: 10.1210/jc.2015-1884. Epub 2015 Jun 18. Review.

38.

Individualized iterative phenotyping for genome-wide analysis of loss-of-function mutations.

Johnston JJ, Lewis KL, Ng D, Singh LN, Wynter J, Brewer C, Brooks BP, Brownell I, Candotti F, Gonsalves SG, Hart SP, Kong HH, Rother KI, Sokolic R, Solomon BD, Zein WM, Cooper DN, Stenson PD, Mullikin JC, Biesecker LG.

Am J Hum Genet. 2015 Jun 4;96(6):913-25. doi: 10.1016/j.ajhg.2015.04.013.

39.

Possible adverse effects of SGLT2 inhibitors on bone.

Taylor SI, Blau JE, Rother KI.

Lancet Diabetes Endocrinol. 2015 Jan;3(1):8-10. doi: 10.1016/S2213-8587(14)70227-X. Epub 2014 Dec 16. No abstract available.

40.

What Parents Think about Giving Nonnutritive Sweeteners to Their Children: A Pilot Study.

Sylvetsky AC, Greenberg M, Zhao X, Rother KI.

Int J Pediatr. 2014;2014:819872. doi: 10.1155/2014/819872. Epub 2014 Nov 4.

41.

Response to comment on Sarkar et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes care 2014;37:666-670.

Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI.

Diabetes Care. 2014 Oct;37(10):e219-20. doi: 10.2337/dc14-1482. No abstract available.

42.
43.

Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.

Christensen JD, Lungu AO, Cochran E, Collins MT, Gafni RI, Reynolds JC, Rother KI, Gorden P, Brown RJ.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1493-500. doi: 10.1210/jc.2014-1353. Epub 2014 Jul 29.

44.

Neck circumference is a predictor of metabolic syndrome and obstructive sleep apnea in short-sleeping obese men and women.

Cizza G, de Jonge L, Piaggi P, Mattingly M, Zhao X, Lucassen E, Rother KI, Sumner AE, Csako G; NIDDK Sleep Extension Study.

Metab Syndr Relat Disord. 2014 May;12(4):231-41. doi: 10.1089/met.2013.0093. Epub 2014 Feb 26.

45.

Sucralose, a synthetic organochlorine sweetener: overview of biological issues.

Schiffman SS, Rother KI.

J Toxicol Environ Health B Crit Rev. 2013;16(7):399-451. doi: 10.1080/10937404.2013.842523. Review.

46.

Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.

Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI.

Diabetes Care. 2014;37(3):666-70. doi: 10.2337/dc13-1473. Epub 2013 Nov 5.

47.

Challenging recruitment of youth with type 2 diabetes into clinical trials.

Nguyen TT, Jayadeva V, Cizza G, Brown RJ, Nandagopal R, Rodriguez LM, Rother KI.

J Adolesc Health. 2014 Mar;54(3):247-54. doi: 10.1016/j.jadohealth.2013.08.017. Epub 2013 Oct 23. Review.

48.

Novel forms of lipodystrophy: why should we care?

Rother KI, Brown RJ.

Diabetes Care. 2013 Aug;36(8):2142-5. doi: 10.2337/dc13-0561. No abstract available.

49.

Obstructive sleep apnea is a predictor of abnormal glucose metabolism in chronically sleep deprived obese adults.

Cizza G, Piaggi P, Lucassen EA, de Jonge L, Walter M, Mattingly MS, Kalish H, Csako G, Rother KI; Sleep Extension Study Group.

PLoS One. 2013 May 29;8(5):e65400. doi: 10.1371/journal.pone.0065400. Print 2013.

50.

Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study.

Price JD, Linder G, Li WP, Zimmermann B, Rother KI, Malek R, Alattar M, Tarbell KV.

Clin Exp Immunol. 2013 Oct;174(1):120-8. doi: 10.1111/cei.12144.

Supplemental Content

Loading ...
Support Center